Neuronetics Q3 revenue up 4% to $18.5M; net loss widens to $13.3M; stockholders approve Greenbrook deal

Neuronetics, Inc.

2024-Q3 EPS reported -$1.04 revenue$52,397,000

Revenue $18.5M (+4% YoY); U.S. system revenue $4.1M (+14%) on 48 units; treatment session revenue $13.3M (+2%)
Gross margin improved to 75.6% from 65.8% due to product mix and absence of prior-year manufacturing costs
Net loss widened to $13.3M ($0.44/sh) from $9.4M ($0.33/sh) in Q3 2023; EBITDA -$11.6M vs -$7.7M; cash $20.9M
Stockholders approved Greenbrook acquisition Nov 8; court hearing Nov 15; expect cash flow breakeven by Q2 2025
Full-year 2024 revenue guidance narrowed to $71-72M; Q4 2024 revenue guidance $19-20M

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.